Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96IL0
UPID:
COA8_HUMAN
Alternative names:
Apoptogenic protein 1, mitochondrial
Alternative UPACC:
Q96IL0; H7C2Z1; Q53G28
Background:
Cytochrome c oxidase assembly factor 8, also known as Apoptogenic protein 1, mitochondrial, plays a crucial role in the assembly and function of cytochrome c complex (COX) IV. This protein is essential for the terminal component of the mitochondrial respiratory chain, safeguarding COX assembly from oxidation-induced degradation.
Therapeutic significance:
The protein is linked to Mitochondrial complex IV deficiency, nuclear type 17, a disorder with a spectrum of clinical manifestations. Understanding the role of Cytochrome c oxidase assembly factor 8 could open doors to potential therapeutic strategies for this mitochondrial disorder, offering hope for targeted treatments.